首页> 外文期刊>The American surgeon. >The Impact of Multidisciplinary Therapy in Node-Positive Rectal Cancer
【24h】

The Impact of Multidisciplinary Therapy in Node-Positive Rectal Cancer

机译:多学科治疗对淋巴结阳性直肠癌的影响

获取原文
获取原文并翻译 | 示例
       

摘要

Multidisciplinary therapy (MDT) of node-positive rectal cancer is considered optimal. We performed a retrospective cohort study of node positive rectal cancer patients diagnosed between January 1,1994 and December 31, 2003 in Region 5 of the California Cancer Registry to determine the impact of MDT on disease specific survival (DSS). During the study period, 398 patients with stage III rectal cancer were identified. Only 251 patients (63.1%) received radiation (XRT). Patients receiving XRT had significantly improved survival when compared with those who did not (5 year DSS 55% with XRT vs 36% without XRT, median follow-up 43 months, P < 0.001). There was no statistically significant difference in T stage (P = 0.41), the number of Nl patients (P = 0.45), or the number of positive nodes harvested (mean 11.5 w/o XRT vs 12.8 w/XRT, P = 0.37) between patients receiving XRT and those who did not. Patients receiving XRT were far more likely to receive systemic chemotherapy (83% vs 27%, P < 0.0001). Multidisciplinary therapy of node-positive rectal cancer is associated with improved DSS. However, substantial numbers of node positive rectal cancer patients are not receiving MDT. Greater efforts are needed to implement consistent multidisciplinary algorithms into rectal cancer management.
机译:淋巴结阳性直肠癌的多学科治疗(MDT)被认为是最佳的。我们对1994年1月1日至2003年12月31日期间在加利福尼亚州癌症登记处诊断为淋巴结阳性的直肠癌患者进行了一项回顾性队列研究,以确定MDT对疾病特异性存活率(DSS)的影响。在研究期间,确定了398例III期直肠癌患者。仅251例患者(63.1%)接受了放射治疗(XRT)。与未接受XRT的患者相比,接受XRT的患者的生存率显着提高(5年DSS接受XRT的患者为55%,未接受XRT的患者为36%,中位随访43个月,P <0.001)。在T期(P = 0.41),Nl患者的数量(P = 0.45)或收获的阳性淋巴结数量(平均11.5 w / o XRT与12.8 w / XRT,P = 0.37)差异无统计学意义。在接受XRT的患者与未接受XRT的患者之间。接受XRT的患者接受全身化疗的可能性要高得多(83%比27%,P <0.0001)。淋巴结阳性直肠癌的多学科治疗与改善DSS有关。但是,许多淋巴结阳性的直肠癌患者未接受MDT。需要付出更大的努力才能在直肠癌治疗中实施一致的多学科算法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号